Aspirin challenge is considered the gold standard for diagnosing AERD. Once the diagnosis is confirmed with a positive challenge result, management involves avoidance of all COX-1-inhibiting drugs or aspirin desensitization, followed by continuous aspirin therapy. Aspirin challenge and desensitization are usually done simultaneously in these patients, and aspirin desensitization will be used hereafter to refer to this combined procedure.
Aspirin desensitization is a provocative procedure and will likely induce symptoms in a patient with AERD. Therefore safety is an important consideration when performing aspirin desensitization in patients with AERD. Certain risk factors have been linked to severe bronchial reactions during aspirin desensitization, including no use of a leukotriene-modifying drug (LTMD) at the time of desensitization, baseline FEV 1 of less than 80% of predicted value, and a history of a prior emergency department visit for asthma. 8 Atopic status, sex, age at disease onset, systemic corticosteroid dependence, and the type or severity of the historical reaction to aspirin/NSAIDs have not been shown to be associated with severity.
Abbreviations used
AERD: Aspirin-exacerbated respiratory disease LTMD: Leukotriene-modifying drug NSAID: Nonsteroidal anti-inflammatory drug PNIF: Peak nasal inspiratory flow SNOT-22: Sino-Nasal Outcome Test
Over the years, modifications to aspirin desensitization protocols have enhanced its safety. One of the best examples of this is the use of LTMDs, such as montelukast, for at least 1 week before aspirin desensitization. [9] [10] [11] LTMDs reduce the intensity of the reactions to aspirin, especially in the lower airways, but typically do not block the reactions completely, which is essential because one goal of desensitization is to confirm the diagnosis of AERD. [9] [10] [11] Another safety modification to the desensitization protocol was the addition of intranasal ketorolac before oral aspirin (Fig 1) . The addition of intranasal ketorolac significantly reduces the mean percentage decrease in FEV 1 measurement, as well as decreasing the risk of extrapulmonary reactions, such as laryngospasm and gastrointestinal symptoms. 12 Despite these modifications that have enhanced safety, a recent survey of aspirin desensitization practices among allergists and fellows in training in the United States indicated that only 62.5% of respondents perform aspirin desensitization for AERD. 13 Of those who do not, nearly 28% do not refer the patient to an allergist who does. Safety concerns, logistics of nursing care, and lack of exposure to the procedure during fellowship training were listed as the primary deterrents to use of desensitization in patients with AERD. This survey highlighted the need for more safety and outcomes data for aspirin desensitization in AERD.
Over the past decade, our group has successfully performed hundreds of outpatient aspirin desensitization procedures without any serious complications, hospitalizations, or deaths. As a result of this familiarity with aspirin desensitization, we sought to address some of the concerns highlighted in the survey and to supply readers with our outcomes and safety data by conducting a 5-year review of our aspirin desensitization procedures. Additionally, we analyzed various patient characteristics to determine which factors, if any, might influence or predict reaction severity.
METHODS
This was an institutional review board-approved review of all aspirin desensitization procedures performed at Scripps Clinic from January 2009 through August 2015. A total of 275 procedures were performed during that time period. Of those, 71 were excluded from chart review because of missing charts (n 5 10), patients declining participation in research (n 5 2), or use of an altered desensitization protocol (n 5 59). This latter group included 3 patients who did not receive ketorolac per patient preference and 56 patients who participated in research projects that involved alterations of the standard desensitization protocol used at Scripps Clinic. The goal of the analysis was to gather information regarding outcomes of desensitization by using the specific protocol described in Fig 1. Therefore patients who did not undergo this protocol were excluded.
The charts of the remaining 204 patients were reviewed in detail. Of the 204 patients, 167 reacted during aspirin desensitization, and this group became the focus of our analysis.
Baseline patient characteristics, such as age, sex, ethnicity, medication use, FEV 1 , and symptom scores, were reviewed. The reactors were then analyzed to assess the type and frequency of induced reactions, treatment provided, and changes in objective measures collected during the procedures. Basic statistical calculations were performed to determine whether any baseline characteristic was predictive of reaction severity during desensitization and to detect differences between reactions to nasal ketorolac and those to oral aspirin.
RESULTS

Patient demographics
Baseline patient characteristics for 167 reactors are presented in Table I . Mean age was 47.2 years, and there were nearly twice as many female as male patients. Mean baseline FEV 1 was 86% of predicted value (range, 37% to 114%). Mean peak nasal inspiratory flow (PNIF) rate was 155.7 L/min. The majority of patients (73.1%) had a history of positive skin test responses to inhalant allergens. Of those, 14.4% were receiving allergy immunotherapy at the time of desensitization. The average number of sinus surgeries was 2.9 (range, 0-12). Twenty-two (13.2%) patients had previously undergone at least 1 aspirin desensitization. The vast majority of patients (98.8%) were receiving an LTMD at the time of desensitization, with montelukast being the most common. Only 4.5% of patients were receiving omalizumab at the time of desensitization, whereas 26.3% were receiving systemic corticosteroids.
Symptom scores
Recently, we began collection of Asthma Control Test and Sino-Nasal Outcome Test (SNOT-22) scores before aspirin desensitization. Therefore only 45 patients had these baseline symptom scores measured during the above review period. Among these patients, the average Asthma Control Test score was 21.8 (range, 11-25); the average SNOT-22 score was 28.7 (range, 2-76). Table II contains data on reaction characteristics. The data are separated into 3 columns to define ketorolac reactors, aspirin reactors, and all reactors. Some patients reacted to both medications during the procedure and were included under both columns. More patients (88%) reacted to ketorolac than to aspirin (38.9%). Most ketorolac reactors (53.1%) reacted to the 7.58-mg dose, whereas most aspirin reactors (83.1%) reacted to one of the 60-mg doses.
Reaction characteristics
Reaction types
Reactions were categorized as follows: Isolated naso-ocular reactions represented 56.5% of the reactions to nasal ketorolac, followed by classical (22.4%), mixed (17.7%), and bronchial (2.7%) reactions. A single patient had an isolated laryngeal reaction to ketorolac. No isolated gastrointestinal reactions and no cutaneous reactions to ketorolac occurred. Isolated naso-ocular reactions were the most common reactions to aspirin as well, comprising 26.2% of the reactions. Classical (23.1%), bronchial (20.0), and mixed (17.0%) reactions were also common. Isolated laryngeal, gastrointestinal, and cutaneous reactions each occurred less than 5% of the time.
Several patients had mixed reactions, meaning they met the criteria for at least 2 of the categories described above. The most common mixed reaction among ketorolac reactors was naso-ocular combined with laryngeal. Among aspirin reactors, naso-ocular with bronchial, classical with gastrointestinal, and bronchial with laryngeal reactions were most common. Looking at all reactors, naso-ocular (43.1%), mixed (32.3%), or classical (18.6%) reactions occurred more than 90% of the time. Isolated bronchial, laryngeal, or cutaneous reactions were far less common. There were no isolated gastrointestinal reactions when all reactors were analyzed together.
Changes in PNIF and FEV 1
The mean decrease in PNIF was 32.4% and 23.0% in ketorolac and aspirin reactions, respectively (P 5 .02). On average, FEV 1 decreased by 11.0% (range, 0% to 63%) and 12.3% (range, 0% to 45%) in ketorolac and aspirin reactions, respectively, but this difference did not reach statistical significance (P 5 .51).
Treatments used during desensitization
Table III summarizes the treatments administered for reactions during aspirin desensitization. The reactors are divided into 3 columns to highlight treatments required for ketorolac reactors, aspirin reactors, and all reactors. Patients reacting to intranasal ketorolac required 3.1 treatments, on average, compared with 2.2 for those reacting to oral aspirin (P 5 .01). Considering all reactors together, the average treatment requirement per patient was 3.6.
Regarding ketorolac reactors, 74.8% received at least 1 antihistamine. Nasal decongestants (52.4%) and bronchodilators (40.8%) were also used frequently. Gastrointestinal medications were prescribed for 7.5% of all ketorolac reactors. A small percentage of ketorolac reactors required intramuscular epinephrine. Up to 15% of all ketorolac reactors did not receive any form of treatment despite having a documented reaction.
Aspirin reactors were most commonly treated with a bronchodilator (56.9%), followed by antihistamines (52.3%), nasal decongestants (18.5%), and gastrointestinal medications (10.8%). No aspirin reactor required intramuscular epinephrine, and 10.8% of aspirin reactors did not receive any treatment.
The final column in Table III looks at treatment frequency among all reactors. Overall, antihistamines were used in 76% of patients. Other commonly used medications were bronchodilators, nasal decongestants, and gastrointestinal medications. Overall, 21 (12.6%) patients did not require any form of treatment despite objective reactions.
Length of desensitization
The average length of desensitization among all reactors was 1.67 days (range, 1-4 days). Among those who had a gastrointestinal reaction, the average length of desensitization was 2.29 days (range, 1.5-4 days; P 5 .006).
Severe reactions
Twenty-three (13.8%) patients had severe reactions during desensitization. We defined a severe reactor as follows:
d required intramuscular epinephrine and/or d required 3 or more doses of a b 2 -agonist and/or had an FEV 1 decrease of 30% or greater. Four patients required intramuscular epinephrine, and 21 required 3 or more doses of a b 2 -agonist and/or had an FEV 1 decrease of 30% or greater. Two of the patients requiring intramuscular epinephrine also met the other criterion. Table IV provides data for each patient requiring epinephrine administration during the desensitization. All 4 patients received epinephrine as treatment for ketorolac reactions.
Gastrointestinal reactors
Of the 17 patients who had a gastrointestinal reaction, 10 had the reaction to nasal ketorolac and 6 to oral aspirin, and a single patient had a gastrointestinal reaction to both ketorolac and aspirin. Eight (47%) of the 17 reported having had a historical gastrointestinal reaction upon aspirin or NSAID ingestion in the past.
Predictive risk factors
The final analysis performed attempted to identify whether any baseline characteristics were predictive of a severe reaction (Table V) . Severe reactors, as defined above, were compared with those who did not have a severe reaction. Severe reactors had a higher mean baseline SNOT-22 score compared with nonsevere reactors (P 5 .05) and might be able to predict severe reactions, but only 45 of 167 participants had a baseline SNOT-22 score. Patients receiving systemic corticosteroids at the time of desensitization were more likely to have a severe reaction. The time interval between the most recent sinus surgery and aspirin desensitization was not found to be predictive of a severe reaction, and that time interval did not correlate with the patient's baseline SNOT-22 score.
Omalizumab use during desensitization
Eight (4.8%) of the 167 reactors were receiving omalizumab during aspirin desensitization. Of the 37 nonreactors, only 1 was receiving omalizumab therapy. Average baseline FEV 1 and PNIF values among these patients was 2.79 L and 85.4% of predicted value and 166.9 L/min, respectively. These measurements were comparable with those of the patients in this study who were not receiving omalizumab. However, the average number of sinus surgeries (5.1) before desensitization was higher in patients receiving omalizumab compared with all reactors (2.9). Fifty percent of the patients receiving omalizumab experienced a decrease in FEV 1 of 15% or greater. There was no difference in the number of treatments received for patients receiving omalizumab versus those not receiving anti-IgE therapy. The average length of desensitization was slightly higher in this subset of patients at 1.8 days compared with 1.67 days for all reactors. None of the patients receiving omalizumab were severe reactors.
DISCUSSION
Aspirin desensitization followed by daily aspirin treatment has long been regarded as an effective treatment modality in patients with AERD. Various safety measures have been implemented in aspirin desensitization protocols to mitigate the risks inherent in a provocative challenge. However, despite the efficacy and improved safety and efficiency of aspirin desensitization, a recent survey found that safety and logistical concerns deter many providers from using aspirin desensitization in the management of AERD. 13 Our current study helps to address these issues and also highlights other features relevant to aspirin desensitization in patients with AERD.
Using criteria consistent with higher severity of reactions, we found that nearly 14% of patients undergoing aspirin desensitization were classified as severe reactors. We also described 4 patients who received intramuscular epinephrine during desensitization. These patients were not hypotensive and did not demonstrate other findings suggestive of an anaphylactic reaction. Rather, it was the combination of symptoms (usually laryngospasm, gastrointestinal symptoms, or both) in light of the entire clinical course that prompted the supervising allergist to use epinephrine to more rapidly resolve the reaction. The percentage of severe reactions is a reminder that these procedures are not without risk and should be performed with proper precautions in place. Yet desensitization was successfully performed in an outpatient setting in 100% of the patients, including severe reactors.
It would certainly be helpful to accurately predict reaction severity based on baseline patient characteristics, but this proves to be difficult. A high SNOT-22 score might be predictive of reaction severity, but this finding requires further study given the smaller numbers of SNOT-22 scores that were collected during the review period. However, it is reasonable to conclude that patients with more active inflammation, particularly of the upper airway, are more likely to experience a significant reaction with COX-1 inhibition.
Despite previous findings by other authors, 8 we did not see a correlation between FEV 1 and reaction severity. This potential ACT, Asthma Control Test; LTRA, leukotriene receptor antagonist. *Forty-five patients had baseline SNOT-22 and ACT scores.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 association might have been missed in our study because of the widespread use of LTMD drugs in our patients. The average baseline FEV 1 measurement among our patients was relatively high at 86% of predicted value, and nearly all were treated with an LTMD before and throughout desensitization, which has been shown to decrease bronchial reaction severity. [9] [10] [11] We also did not see a correlation between age and reaction severity, as seen in prior studies. 8, 14 However, it is important to point out that the definition of a severe reaction is arbitrary and is not necessarily consistent across different studies. This study addresses an important safety issue, which is the development of gastrointestinal symptoms during desensitization. In our experience gastrointestinal reactions during desensitization can be severe and frequently prolong desensitization. Half of the gastrointestinal reactors in our study had no reported historical gastrointestinal reaction to aspirin or H2, Histamine 2 receptor. *Each patient might have received more than 1 type of medication within a medication class (eg, nasal and ocular antihistamines), and therefore the number of specific medications within each medication class will not necessarily add up to the number of patients treated with that medication class.
other NSAIDs. Thus in this group of gastrointestinal reactors, a history of previous gastrointestinal reaction can predict a similar reaction during desensitization, but many patients will experience a gastrointestinal reaction for the first time during their desensitization. In our series 5.3% (9/167) had a gastrointestinal reaction in the absence of a history. This requires some degree of caution in terms of protocol choice. A rapid protocol can lead to administration of an additional dose of medication while a reaction is already progressing, which could lead to a more significant gastrointestinal reaction. As mentioned previously, one of the other common deterrents to performing aspirin desensitization is logistics, including the time commitment required from both patients and providers. Balancing efficiency with safety is certainly an important consideration in aspirin desensitization. A recent publication by Chen et al 15 proposed an hourly dose-escalation protocol with an average desensitization length of 1.60 days in their 57 patients. This average included 9 patients who had a silent desensitization, which requires less time to perform. In our study patients required an average of 1.67 days to complete desensitization, and this number did not include any nonreactors. Furthermore, this number was reduced to an average of 1.60 days when excluding gastrointestinal reactors.
A faster protocol might be useful in some patients, but selecting which patients are appropriate candidates remains problematic. We did have a small percentage of patients (12.6%) with only mild reactions during desensitization and no need for treatment, which might make them suitable candidates for more rapid desensitization protocols. However, given the difficulty in predicting reaction severity and the possibility of dose stacking, the hourly dose-escalation protocol will need to be approached with caution.
Our study addresses another important topic in aspirin desensitization in patients with AERD, which is the role of omalizumab. A few case reports suggest a potential benefit of omalizumab use during aspirin desensitization. In a small total number of patients with AERD who received omalizumab treatment during aspirin desensitization, respiratory symptoms were significantly reduced or even absent after provocation with oral aspirin. [16] [17] [18] Omalizumab was discontinued in some of these patients, and subsequent aspirin challenges were able to elicit typical aspirin-provoked symptoms. A recent double-blind randomized trial of patients with AERD undergoing aspirin desensitization while receiving omalizumab also showed attenuation of aspirin-induced respiratory reactions compared with those receiving placebo. 19 These authors suggest that omalizumab might be able to restore aspirin tolerance without the need for aspirin desensitization. Yet if omalizumab can truly diminish the response to aspirin, it might introduce diagnostic uncertainty in those who do not react.
However, in our study we did not find any clear difference in reaction type or severity among those receiving omalizumab compared with those not receiving it during the time of aspirin desensitization. Furthermore, all 8 patients in our study had objective upper and/or lower airways reactions that did not appear to be blunted by the medication. Our data do not support the findings suggested by recent case reports. It is the authors' opinion that omalizumab remains an option for patients with AERD who are unable to complete aspirin desensitization or continue to have poorly controlled symptoms after desensitization. However, given the small number of patients receiving omalizumab in our study, more studies will need to be conducted to determine whether any true benefit can be obtained from using omalizumab during or in place of aspirin desensitization.
In summary, the safety and efficiency of in-office oral aspirin desensitization have improved and will likely continue to improve, thus making it a viable option for patients with AERD. The consistent theme of this and other studies of aspirin desensitization is that the reactions, even when more severe, are J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 able to be managed in an outpatient setting. There might be circumstances that make it difficult for individual offices to perform aspirin desensitization, but the opportunity to discuss this treatment option should be made available to each patient with AERD. Unfortunately, it is still difficult to predict who will have minimal symptoms and thus could be eligible for a faster dosing protocol or who will have more severe symptoms and require a multiday desensitization. Developing biomarkers or clinical scores to predict desensitization reactions are ideal targets for future study.
